Madrigal Pharmaceuticals, Inc. (MDGL)
NASDAQ: MDGL · Real-Time Price · USD
480.77
+6.49 (1.37%)
At close: Jun 12, 2026, 4:00 PM EDT
480.77
0.00 (0.00%)
After-hours: Jun 12, 2026, 4:58 PM EDT
Madrigal Pharmaceuticals Employees
Madrigal Pharmaceuticals had 915 employees as of December 31, 2025. The number of employees increased by 387 or 73.30% compared to the previous year.
Employees
915
Change (1Y)
387
Growth (1Y)
73.30%
Revenue / Employee
$1,237,694
Profits / Employee
-$338,183
Market Cap
11.08B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 915 | 387 | 73.30% |
| Dec 31, 2024 | 528 | 152 | 40.43% |
| Dec 31, 2023 | 376 | 284 | 308.70% |
| Dec 31, 2022 | 92 | 21 | 29.58% |
| Dec 31, 2021 | 71 | 29 | 69.05% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| BioMarin Pharmaceutical | 3,221 |
| Ionis Pharmaceuticals | 1,402 |
| Axsome Therapeutics | 1,220 |
| Ascendis Pharma | 1,189 |
| Exelixis | 1,077 |
| BridgeBio Pharma | 839 |
| Arrowhead Pharmaceuticals | 711 |
| Cytokinetics | 673 |
MDGL News
- 1 day ago - Madrigal Pharmaceuticals price target lowered to $542 from $550 at BofA - TheFly
- 2 days ago - Madrigal Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 8 days ago - Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 9 days ago - Madrigal Pharmaceuticals to Participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026 - GlobeNewsWire
- 16 days ago - Madrigal Pharmaceuticals announces new analyses of Rezdiffra data - TheFly
- 16 days ago - Madrigal Presents Data Demonstrating Rezdiffra Reduced Markers of Cardiovascular and Liver-Related Risk in Patients with MASH - GlobeNewsWire
- 23 days ago - Madrigal to Present New Data from the Company's MASH Program at EASL 2026 Demonstrating the Effects of Rezdiffra on Markers of Cardiovascular and Portal Hypertension Risk - GlobeNewsWire
- 4 weeks ago - Madrigal Pharmaceuticals price target raised to $709 from $640 at Truist - TheFly